Dominating Diabetes Deals
Intarcia Therapeutics' fundraising is all the more impressive because it is an anomaly in the endocrine diseases space, as a June 11 report from the Biotechnology Industry Organization suggests.
You may also be interested in...
US Hemp Industry Group Rings Alarm With Congress About FDA’s Safety Conclusions
US Hemp Roundtable general counsel cautions congressional leaders about “agency’s misguided use of incomplete safety data as the basis for its continued refusal to regulate CBD as a dietary supplement or food additive.”
Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements
Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.
One-Page Patient Medication Information Document Moves Forward Under Proposed Rule
After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.